Cite
MLA Citation
Martine Bagot et al.. “IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.” Lancet oncology, vol. 20, no. 8, 2019, pp. 1160–1170. http://access.bl.uk/ark:/81055/vdc_100088833042.0x000010